Inhibidores orales de PCSK9: entre la promesa y la evidencia pendiente

Q: What is the clinical evidence from this study?

Study design: Letter. Population: Hypercholesterolemia / Atherosclerotic cardiovascular disease (ASCVD). Intervention: Oral PCSK9 inhibitors (including enlicitide) vs. Placebo, ezetimibe, and bempedoic acid. Primary outcome: LDL cholesterol (LDL-C) reduction.

Fernando Vichi

doi:10.7775/rac.es.v94.i5.21046

October 29, 2026Revista Argentina de CardiologíaOpen Access

Inhibidores orales de PCSK9: entre la promesa y la evidencia pendiente

View Full Paper

Ask AI

Bookmark

Share

Key Points

Evaluate the therapeutic potential, limitations, and missing cardiovascular outcome evidence for emerging oral PCSK9 inhibitors.
Correspondence and author response analyzing available clinical evidence, trial pipelines (including NCT06008756), and therapeutic barriers in lipid management.
Oral PCSK9 inhibitors achieve substantial reductions in low-density lipoprotein cholesterol (C-LDL), providing a potential oral alternative to injectable monoclonal antibodies and inclisiran.
Cardiovascular outcome data remain currently absent for this drug class, with long-term benefits dependent on completion of ongoing randomized trials.
Potential economic benefits, such as reduced costs and increased market competition relative to parenteral biologics, remain hypothetical and dependent on regional pricing.

Structured PICO

I

Intervention

Oral PCSK9 inhibitors (5 agents evaluated in the discussed meta-analysis, including enlicitide)

C

Comparator

Placebo, or oral nonstatin therapies (ezetimibe and bempedoic acid)

O

Outcome

Low-density lipoprotein cholesterol (LDL-C) reductionsurrogate

Limitations

Small number of included studies in the discussed meta-analysis
Short follow-up duration (mostly not exceeding 12 weeks)
High statistical heterogeneity for lipoprotein(a) results (I² = 99.2%)
Lack of data on hard clinical cardiovascular outcomes
Small number of available studies
Short follow-up duration (not exceeding 12 weeks in most studies)
Marked statistical heterogeneity for lipoprotein(a) (I² = 99.2%)
Uncertain pricing and market access across different countries

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

This letter to the editor and author reply highlight that while oral PCSK9 inhibitors achieve substantial LDL-C reductions (~58%) comparable to injectable agents, their definitive clinical adoption awaits long-term follow-up and hard cardiovascular outcomes data from ongoing trials like CORALreef Outcomes.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Fernando Vichi (2026) conducted a letter in Hypercholesterolemia / Atherosclerotic cardiovascular disease (ASCVD). Oral PCSK9 inhibitors (including enlicitide) vs. Placebo, ezetimibe, and bempedoic acid was evaluated on LDL cholesterol (LDL-C) reduction. Oral PCSK9 inhibitors reduced LDL cholesterol by approximately 58% compared to placebo in a recent meta-analysis, though clinical cardiovascular outcomes remain pending.

synapsesocial.com/papers/6aee6c1171a7594806220d13 https://doi.org/10.7775/rac.es.v94.i5.21046

View Full Paper

Ask AI

Bookmark

Share

Inhibidores orales de PCSK9: entre la promesa y la evidencia pendiente

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Inhibidores orales de PCSK9: entre la promesa y la evidencia pendiente

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading